It's time to phase out “serologic weak D phenotype” and resolve D types with <i>RHD</i> genotyping including weak D type 4

Abstract

CDS, JTQ, LMK, SGS and WAF have disclosed no conflicts of interest. CMW has received speaker honorarium from Grifols and Immucor and consulting honorarium from Quotient, Cerus, and ArchOncology with renumeration to New York Blood Center. GAD and MAK are on the Grifols Speakers Bureau. MD has received speaker honorarium from Grifols. RV receives financial support from bioMérieux, Cerus, Fresenius-Kabi, Hemanext, and Hemastrat. STJ receives speaker honorarium from Grifols and Immucor.